Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.62 |
| ▸ | SERPINC1 | P01008 | 3/20 | 0.47 |
| ▸ | FGF1 | P05230 | 4/20 | 0.42 |
| ▸ | BDNF | P23560 | 3/20 | 0.40 |
| ▸ | PTN | P21246 | 2/20 | 0.40 |
| ▸ | MDK | P21741 | 2/20 | 0.40 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.39 |
| ▸ | CCL2 | P13500 | 1/20 | 0.39 |
| ▸ | CCL5 | P13501 | 1/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | FGF2 | P09038 | 2/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13796405 | 1.00 | F10 (0.62) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL15171284 | 0.91 | F10 (0.69) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL14817755 | 0.91 | F10 (0.69) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL19619414 | 0.91 | F10 (0.69) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL15296510 | 0.88 | F10 (0.65) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL15171262 | 0.88 | F10 (0.65) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL27433034 | 0.85 | F10 (0.61) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL13795898 | 0.84 | F10 (0.85) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL10148985 | 0.84 | F10 (0.85) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL16418343 | 0.81 | F10 (0.58) | F10SERPINC1FGF1BDNFPTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114970-B2 | Synthetic heparin monosaccharides | ALCHEMIA LIMITED (AU) | 2012-02-14 | — | — | US | disclosed |
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LIMITED (AU) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | HPSE, DDOST, STT3A | F10 107/4885SERPINC1 8/4885FGF1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.